The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Drug for Ulcerative Colitis-Global Market Insights and Sales Trends 2025
Synopsis
Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum).
The global Drug for Ulcerative Colitis market size is expected to reach US$ 11250 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The market is mainly driven by the significant applications of Drug for Ulcerative Colitis in various end use industries. The expanding demands from the Hospital and Drugs Stores, are propelling Drug for Ulcerative Colitis market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Injection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drug for Ulcerative Colitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drug for Ulcerative Colitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drug for Ulcerative Colitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drug for Ulcerative Colitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drug for Ulcerative Colitis covered in this report include Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson and Bayer, etc.
The global Drug for Ulcerative Colitis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Roche
Sanofi
GSK
AstraZeneca
MSD
Johnson & Johnson
Bayer
AbbVie
Eli Lilly and Company
Amgen
Takeda Pharmaceuticals Company
Ferring Pharmaceuticals
InDeX Pharmaceuticals
Global Drug for Ulcerative Colitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drug for Ulcerative Colitis market, Segment by Type:
Oral
Injection
Global Drug for Ulcerative Colitis market, by Application
Hospital
Drugs Stores
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drug for Ulcerative Colitis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum).
The global Drug for Ulcerative Colitis market size is expected to reach US$ 11250 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The market is mainly driven by the significant applications of Drug for Ulcerative Colitis in various end use industries. The expanding demands from the Hospital and Drugs Stores, are propelling Drug for Ulcerative Colitis market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Injection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drug for Ulcerative Colitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drug for Ulcerative Colitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drug for Ulcerative Colitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drug for Ulcerative Colitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drug for Ulcerative Colitis covered in this report include Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson and Bayer, etc.
The global Drug for Ulcerative Colitis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Roche
Sanofi
GSK
AstraZeneca
MSD
Johnson & Johnson
Bayer
AbbVie
Eli Lilly and Company
Amgen
Takeda Pharmaceuticals Company
Ferring Pharmaceuticals
InDeX Pharmaceuticals
Global Drug for Ulcerative Colitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drug for Ulcerative Colitis market, Segment by Type:
Oral
Injection
Global Drug for Ulcerative Colitis market, by Application
Hospital
Drugs Stores
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drug for Ulcerative Colitis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Drug for Ulcerative Colitis
1.1 Drug for Ulcerative Colitis Market Overview
1.1.1 Drug for Ulcerative Colitis Product Scope
1.1.2 Drug for Ulcerative Colitis Market Status and Outlook
1.2 Global Drug for Ulcerative Colitis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Drug for Ulcerative Colitis Market Size by Region (2018-2029)
1.4 Global Drug for Ulcerative Colitis Historic Market Size by Region (2018-2023)
1.5 Global Drug for Ulcerative Colitis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Drug for Ulcerative Colitis Market Size (2018-2029)
1.6.1 North America Drug for Ulcerative Colitis Market Size (2018-2029)
1.6.2 Europe Drug for Ulcerative Colitis Market Size (2018-2029)
1.6.3 Asia-Pacific Drug for Ulcerative Colitis Market Size (2018-2029)
1.6.4 Latin America Drug for Ulcerative Colitis Market Size (2018-2029)
1.6.5 Middle East & Africa Drug for Ulcerative Colitis Market Size (2018-2029)
2 Drug for Ulcerative Colitis Market by Type
2.1 Introduction
2.1.1 Oral
2.1.2 Injection
2.2 Global Drug for Ulcerative Colitis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Drug for Ulcerative Colitis Historic Market Size by Type (2018-2023)
2.2.2 Global Drug for Ulcerative Colitis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Drug for Ulcerative Colitis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Drug for Ulcerative Colitis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Drug for Ulcerative Colitis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Drug for Ulcerative Colitis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Drug for Ulcerative Colitis Revenue Breakdown by Type (2018-2029)
3 Drug for Ulcerative Colitis Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Drugs Stores
3.2 Global Drug for Ulcerative Colitis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Drug for Ulcerative Colitis Historic Market Size by Application (2018-2023)
3.2.2 Global Drug for Ulcerative Colitis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Drug for Ulcerative Colitis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Drug for Ulcerative Colitis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Drug for Ulcerative Colitis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Drug for Ulcerative Colitis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Drug for Ulcerative Colitis Revenue Breakdown by Application (2018-2029)
4 Drug for Ulcerative Colitis Competition Analysis by Players
4.1 Global Drug for Ulcerative Colitis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drug for Ulcerative Colitis as of 2022)
4.3 Date of Key Players Enter into Drug for Ulcerative Colitis Market
4.4 Global Top Players Drug for Ulcerative Colitis Headquarters and Area Served
4.5 Key Players Drug for Ulcerative Colitis Product Solution and Service
4.6 Competitive Status
4.6.1 Drug for Ulcerative Colitis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Drug for Ulcerative Colitis Products, Services and Solutions
5.1.4 Pfizer Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Drug for Ulcerative Colitis Products, Services and Solutions
5.2.4 Novartis Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Roche
5.3.1 Roche Profile
5.3.2 Roche Main Business
5.3.3 Roche Drug for Ulcerative Colitis Products, Services and Solutions
5.3.4 Roche Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Drug for Ulcerative Colitis Products, Services and Solutions
5.4.4 Sanofi Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 GSK
5.5.1 GSK Profile
5.5.2 GSK Main Business
5.5.3 GSK Drug for Ulcerative Colitis Products, Services and Solutions
5.5.4 GSK Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.5.5 GSK Recent Developments
5.6 AstraZeneca
5.6.1 AstraZeneca Profile
5.6.2 AstraZeneca Main Business
5.6.3 AstraZeneca Drug for Ulcerative Colitis Products, Services and Solutions
5.6.4 AstraZeneca Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.6.5 AstraZeneca Recent Developments
5.7 MSD
5.7.1 MSD Profile
5.7.2 MSD Main Business
5.7.3 MSD Drug for Ulcerative Colitis Products, Services and Solutions
5.7.4 MSD Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.7.5 MSD Recent Developments
5.8 Johnson & Johnson
5.8.1 Johnson & Johnson Profile
5.8.2 Johnson & Johnson Main Business
5.8.3 Johnson & Johnson Drug for Ulcerative Colitis Products, Services and Solutions
5.8.4 Johnson & Johnson Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.8.5 Johnson & Johnson Recent Developments
5.9 Bayer
5.9.1 Bayer Profile
5.9.2 Bayer Main Business
5.9.3 Bayer Drug for Ulcerative Colitis Products, Services and Solutions
5.9.4 Bayer Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.9.5 Bayer Recent Developments
5.10 AbbVie
5.10.1 AbbVie Profile
5.10.2 AbbVie Main Business
5.10.3 AbbVie Drug for Ulcerative Colitis Products, Services and Solutions
5.10.4 AbbVie Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.10.5 AbbVie Recent Developments
5.11 Eli Lilly and Company
5.11.1 Eli Lilly and Company Profile
5.11.2 Eli Lilly and Company Main Business
5.11.3 Eli Lilly and Company Drug for Ulcerative Colitis Products, Services and Solutions
5.11.4 Eli Lilly and Company Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.11.5 Eli Lilly and Company Recent Developments
5.12 Amgen
5.12.1 Amgen Profile
5.12.2 Amgen Main Business
5.12.3 Amgen Drug for Ulcerative Colitis Products, Services and Solutions
5.12.4 Amgen Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.12.5 Amgen Recent Developments
5.13 Takeda Pharmaceuticals Company
5.13.1 Takeda Pharmaceuticals Company Profile
5.13.2 Takeda Pharmaceuticals Company Main Business
5.13.3 Takeda Pharmaceuticals Company Drug for Ulcerative Colitis Products, Services and Solutions
5.13.4 Takeda Pharmaceuticals Company Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.13.5 Takeda Pharmaceuticals Company Recent Developments
5.14 Ferring Pharmaceuticals
5.14.1 Ferring Pharmaceuticals Profile
5.14.2 Ferring Pharmaceuticals Main Business
5.14.3 Ferring Pharmaceuticals Drug for Ulcerative Colitis Products, Services and Solutions
5.14.4 Ferring Pharmaceuticals Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.14.5 Ferring Pharmaceuticals Recent Developments
5.15 InDeX Pharmaceuticals
5.15.1 InDeX Pharmaceuticals Profile
5.15.2 InDeX Pharmaceuticals Main Business
5.15.3 InDeX Pharmaceuticals Drug for Ulcerative Colitis Products, Services and Solutions
5.15.4 InDeX Pharmaceuticals Drug for Ulcerative Colitis Revenue (US$ Million) & (2018-2023)
5.15.5 InDeX Pharmaceuticals Recent Developments
6 North America
6.1 North America Drug for Ulcerative Colitis Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Drug for Ulcerative Colitis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Drug for Ulcerative Colitis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Drug for Ulcerative Colitis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Drug for Ulcerative Colitis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Drug for Ulcerative Colitis Market Dynamics
11.1 Drug for Ulcerative Colitis Industry Trends
11.2 Drug for Ulcerative Colitis Market Drivers
11.3 Drug for Ulcerative Colitis Market Challenges
11.4 Drug for Ulcerative Colitis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
